Association between serum LDH and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma: supplemental materials

The first file details the methodological approach and results of survival analysis using Cox proportional hazards regression modeling to examine the relationship between LDH level and progression-free (PFS) or overall survival (OS) among all patients in our cohort. Results demonstrated that elevated serum LDH at >3 months after ICI initiation was significantly associated with worse PFS (HR: 2.81; p<0.001) and OS (HR: 4.77; p<0.001). There were no significant relationships between PFS or OS when examining LDH level at baseline. These results suggest that having an elevated LDH at the >3 month time point is representative of metastatic burden and may be more of a marker for lack of response to ICIs rather than a predictor of survival outcomes. It is possible that our smaller sample size was insufficiently powered to detect survival outcomes but more appropriate for detecting cutaneous immune-related adverse event (cirAE) outcomes. The second file includes Supplemental Table 1.